Key result
Review details etiology, diagnosis, and protective lifestyle adjustments for fetal cardiac hypertrophy linked to maternal diabetes.
Why the study?
To address the etiology, diagnosis, pathogenesis, and protection from cardiac hypertrophy as a teratological disorder in the embryo.
Answers are grounded in this paper and cite their sources.
This review outlines the etiology, diagnosis, pathogenesis, and prevention of fetal cardiac hypertrophy in high-risk pregnancies.
Cardiac hypertrophy is a chief dangerous factor for heart failure, which is the leading cause of child mortality among birth defects internationally. It is a disorder that is defined by the heart muscle thickening, which expands the size of the heart chambers to improve the heart's capacity to pump blood into the body's tissues and organs. Pregnant women with a family history, of pre-gestational diabetes mellitus (PGDM), preeclampsia, or hypertension are at high risk of carrying a fetus with cardiac hypertrophy. These inborn developmental defects might include various cardiac defects along with fetal cardiomyopathy. Symptoms of the disease vary from minor to major and may include chest pain, as well as dyspnea. It is diagnosed based on medical history, a physical exam and echocardiogram results. Protection and treatment of the unborn fetus with cardiac hypertrophy can be achieved via lifestyle adjustment, obesity avoidance, medications and sometimes procedures. The aim of the current research is to address the etiology, diagnosis, pathogenesis and protection from cardiac hypertrophy as a teratological disorder in embryo.
No takes yet. Share an insight, caveat, or question.
Ateef et al. (2022) conducted a review in Fetal cardiac hypertrophy. Fetal cardiac hypertrophy, a teratological disorder linked to maternal diabetes and hypertension, is addressed regarding its etiology, diagnosis, pathogenesis, and protective lifestyle adjustments.
Synapse has enriched 10 related papers. Consider them for comparative context: